Log In
BCIQ
Print this Print this
 

Solesta

  Manage Alerts
Collapse Summary General Information
Company Galderma S.A.
DescriptionInjectable hyaluronic acid biocompatible gel
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacromolecule: Polysaccharide
Latest Stage of DevelopmentMarketed
Standard Indication Gastrointestinal (unspecified)
Indication DetailsTreat fecal incontinence
Regulatory Designation
PartnerValeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$12,944.0M

$11,989.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today